After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...